Baseline demographic and disease characteristics
| Characteristic . | N = 841 . |
|---|---|
| Median age, (range), y | 67 (18-100) |
| Age categories, n (%) | |
| <40 y | 59 (7.0) |
| ≥40 y to <65 y | 285 (33.9) |
| ≥65 y to <75 y | 308 (36.6) |
| ≥75 y | 189 (22.5) |
| Sex, n (%) | |
| Male | 416 (49.5) |
| Female | 425 (50.5) |
| Race, n (%) | |
| White | 538 (64.0) |
| Asian | 82 (9.7) |
| Black | 42 (5.0) |
| Other or unknown | 179 (21.3) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 49 (5.8) |
| Not Hispanic/Latino | 577 (68.6) |
| Not reported or unknown | 215 (25.6) |
| Baseline ECOG PS 0-1, n (%) | 682 (81.2) |
| Pre-existing cardiac disorder, n (%) | 293 (34.8) |
| Pre-existing pulmonary disorder, n (%) | 395 (47.0) |
| Baseline total bilirubin >1.5 × ULN, n (%) | 10 (1.2) |
| Baseline creatinine clearance <45 mL/min, n (%) | 41 (4.9) |
| Disease status | |
| Untreated AML, n (%) | 33 (3.9) |
| Primary refractory AML, n (%) | 329 (39.1) |
| Untreated relapse AML, n (%) | 369 (43.9) |
| Refractory relapse AML, n (%) | 110 (13.1) |
| Median number of relapses (range) | 1 (0-3) |
| Prior stem cell transplantation, n (%) | 144 (17.1) |
| Transfusion dependent at baseline, n (%)∗ | 543 (64.6) |
| Characteristic . | N = 841 . |
|---|---|
| Median age, (range), y | 67 (18-100) |
| Age categories, n (%) | |
| <40 y | 59 (7.0) |
| ≥40 y to <65 y | 285 (33.9) |
| ≥65 y to <75 y | 308 (36.6) |
| ≥75 y | 189 (22.5) |
| Sex, n (%) | |
| Male | 416 (49.5) |
| Female | 425 (50.5) |
| Race, n (%) | |
| White | 538 (64.0) |
| Asian | 82 (9.7) |
| Black | 42 (5.0) |
| Other or unknown | 179 (21.3) |
| Ethnicity, n (%) | |
| Hispanic/Latino | 49 (5.8) |
| Not Hispanic/Latino | 577 (68.6) |
| Not reported or unknown | 215 (25.6) |
| Baseline ECOG PS 0-1, n (%) | 682 (81.2) |
| Pre-existing cardiac disorder, n (%) | 293 (34.8) |
| Pre-existing pulmonary disorder, n (%) | 395 (47.0) |
| Baseline total bilirubin >1.5 × ULN, n (%) | 10 (1.2) |
| Baseline creatinine clearance <45 mL/min, n (%) | 41 (4.9) |
| Disease status | |
| Untreated AML, n (%) | 33 (3.9) |
| Primary refractory AML, n (%) | 329 (39.1) |
| Untreated relapse AML, n (%) | 369 (43.9) |
| Refractory relapse AML, n (%) | 110 (13.1) |
| Median number of relapses (range) | 1 (0-3) |
| Prior stem cell transplantation, n (%) | 144 (17.1) |
| Transfusion dependent at baseline, n (%)∗ | 543 (64.6) |
ECOG PS, Eastern Cooperative Oncology Group performance status; ULN, upper limit of normal.
Patients were defined as transfusion dependent at baseline if they received any red blood cell or platelet transfusion within 56 days before the first dose of study drug.